Clinical Study
Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients
Table 3
Effects of L-carnitine in BCAA+ patients.
| | Parameter (mean ± SD) | Pretreatment | After TACE | | 1 week | 4 weeks | 12 weeks |
| | Control group () | CP score | 6 ± 1.04 | 6.5 ± 1.16 | 6.25 ± 1.28 | 6.64 ± 1.69 | | S. albumin (g/dL) | 3.25 ± 0.52 | 2.81 ± 0.55 | 3.25 ± 0.51 | 3.01 ± 0.52 | | PT (%) | 87.4 ± 17.3 | 83.4 ± 19.1 | 88.4 ± 18.3 | 83.6 ± 19.8 | | T. bilirubin (mg/dL) | 1.1 ± 0.58 | 1.2 ± 0.55 | 1.05 ± 0.63 | 1.41 ± 0.63 | | ALT (IU/L) | 43.5 ± 19.3 | 56.5 ± 26.6 | 42.9 ± 19.8 | 38.4 ± 11.4 | | AST (IU/L) | 52.4 ± 20.4 | 45.8 ± 9 | 50 ± 21 | 52.7 ± 21.1 | | GGTP (IU/L) | 80.4 ± 93.9 | 104.3 ± 140.5 | 116.3 ± 120 | 43.9 ± 32.3 | | Ascitis (no/moderate/massive) | 8/4/0 | 8/3/1 | 6/4/2 | 6/4/2 | | Encephalopathy (no/yes) | 12/0 | 12/0 | 12/0 | 12/0 |
| | L-carnitine group () | CP score | 6.25 ± 1.6 | 6.38 ± 0.88 | 5.88 ± 0.8 | 5.93 ± 0.99 | | S. albumin (g/dL) | 3.13 ± 0.61 | 2.97 ± 0.42 | 3.25 ± 0.56 | 3.16 ± 0.49 | | PT (%) | 87.2 ± 20.7 | 92.3 ± 16.1 | 94.1 ± 18.2 | 91.6 ± 14.2 | | T. Bilirubin (mg/dL) | 1.01 ± 0.62 | 1.02 ± 0.62 | 0.95 ± 0.53 | 1.1 ± 0.78 | | ALT (IU/L) | 32.2 ± 12.5 | 42.7 ± 22.6 | 30.6 ± 8.3 | 36.1 ± 11 | | AST (IU/L) | 51.7 ± 25.3 | 51.2 ± 31.9 | 51.3 ± 18.7 | 53.5 ± 16.8 | | GGTP (IU/L) | 62 ± 53.7 | 72.8 ± 56.6 | 70.6 ± 36.8 | 60.4 ± 38.5 | | Ascitis (no/moderate/massive) | 14/2/0 | 14/2/0 | 16/0/0 | 15/0/1 | | Encephalopathy (no/yes) | 16/0 | 16/0 | 16/0 | 16/0 |
|
|
SD: standard deviation; CP: Child-Pugh; S. albumin: serum albumin; PT: prothrombin time; T. bilirubin: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGTP: gamma-glutamyl transpeptidase; TACE: transarterial chemoembolization.
Significant difference compared with baseline; significant difference compared with 1 week after TACE; ; .
|
